ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

NRSN NeuroSense Therapeutics Ltd

1,26
-0,09 (-6,67%)
02 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
NeuroSense Therapeutics Ltd NRSN NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
-0,09 -6,67% 1,26 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
1,37 1,24 1,42 1,26 1,35
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
22.4.202414:30PRNUSNeuroSense and Genetika+ Initiate Precision Medicine..
18.4.202414:30PRNUSNeuroSense Presents Positive Data Validating Phase 2b..
12.4.202414:30PRNUSNeuroSense to Present PARADIGM Data at the American Academy..
11.4.202401:16PRNUSNeuroSense Announces Pricing of $4.5 Million Registered..
09.4.202414:30PRNUSNeuroSense Collaborates with Lonza to Identify Exosome-based..
05.4.202415:29PRNUSNeuroSense Announces Year End 2023 Financial Results and..
22.2.202414:25EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21.2.202414:30PRNUSNeuroSense Reports Additional Positive Results from its ALS..
13.2.202419:20EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13.2.202416:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07.2.202415:38EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07.2.202415:27PRNUSNeuroSense Regains Compliance with NASDAQ Minimum Bid Price..
09.1.202414:49EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09.1.202414:48EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09.1.202414:45PRNUSNeuroSense Recaps Positive 2023 Achievements Including..
27.12.202323:03EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
27.12.202323:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27.12.202323:00PRNUSNeuroSense Announces Receipt of Nasdaq Notice Regarding..
21.12.202314:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14.12.202322:30EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14.12.202315:41EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14.12.202315:24PRNUSNeuroSense Reports New Data: Statistically Significant..
05.12.202321:15EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
05.12.202321:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
05.12.202314:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05.12.202314:00PRNUSNeuroSense's Phase 2b ALS Trial Achieves Primary Safety and..
05.12.202306:15EDGAR2Form EFFECT - Notice of Effectiveness
04.12.202322:01PRNUSNeuroSense to Report Phase 2b ALS Topline Primary Safety and..
04.12.202312:17EDGAR2Form POS AM - Post-Effective amendments for registration..
28.11.202315:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28.11.202314:45PRNUSNeuroSense Announces Third Quarter 2023 Financial Results..
21.11.202316:36EDGAR2Form POS AM - Post-Effective amendments for registration..
13.11.202315:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13.11.202315:20PRNUSNeuroSense Receives U.S. FDA Confirmation of CMC Strategy..
09.11.202315:00PRNUSNeuroSense Therapeutics to Present at Upcoming U.S. and..
06.11.202314:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06.11.202314:30PRNUSNeuroSense Completes Dosing of Last Patient in the..
01.11.202314:00PRNUSNeuroSense Therapeutics to Participate in BIO-Europe Fall
17.10.202314:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17.10.202314:30PRNUSNeuroSense CEO Provides Q3 2023 Update
04.10.202315:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04.10.202315:10PRNUSNeuroSense's PrimeC Demonstrates Outstanding Effect on ALS..
02.10.202317:39EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20.9.202315:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20.9.202315:05PRNUSEuropean Medicines Agency Grants NeuroSense SME Status
19.9.202315:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19.9.202315:00PRNUSNeuroSense Granted Patents in Europe, Japan, and Israel for..
14.9.202315:00PRNUSNeuroSense to Participate in Upcoming ALS Conferences:..
12.9.202315:20EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07.9.202322:31EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]

Kürzlich von Ihnen besucht

Delayed Upgrade Clock